Vitura Health (ASX:VIT) has appointed experienced healthcare executive Justin James as its new chief executive officer, marking a significant leadership shift as the company positions itself for further expansion in emerging therapies and digital health services.
The Melbourne-based company announced that Mr James will formally take on the role from 1 June 2026, bringing with him a track record spanning healthcare leadership, governance, risk management and large-scale business transformation. His appointment follows what the board described as an extensive domestic and global search for a leader capable of executing the company’s next phase of strategy.
Mr James most recently served as chief executive of the Health Insurance Fund of Australia, where he oversaw annual revenue of between $150 million and $180 million, a workforce of more than 150 employees and coverage for around 100,000 members. During his tenure, he led a multi-year turnaround that delivered consistent profitability, supported by tighter financial controls and improved operational discipline.
His experience also extends into emerging and specialty therapies, a core focus for Vitura. While at HIF, he introduced member access and rebates for medicinal cannabis and advanced coverage design for treatments involving psilocybin and MDMA, while also advocating publicly on mental health and smoking cessation initiatives.
Vitura chair Robert Iervasi said the appointment reflects the company’s ambition to scale both commercially and clinically in a rapidly evolving healthcare landscape. “We’re delighted to announce Justin’s appointment after a thorough domestic and global search for an execution-focused leader with a demonstrated track record of success in healthcare and emerging therapies,” he said.
He added that Mr James aligns well with the company’s strategic direction. “Justin has an excellent understanding of the Australian healthcare sector and a proven track record delivering commercial success. His leadership is underpinned by strong governance and risk frameworks in both private and publicly listed organisations, with close relationships with the Board of Directors.”
Mr Iervasi said Mr James’ outlook matches Vitura’s focus on expanding access to new forms of treatment. “His strategic alignment with Vitura was demonstrated by a motivation to expand patient access and informed choice in speciality and emerging therapies. This mirrors Vitura’s positioning across medicinal cannabis, psychedelic-assisted therapies, mental health and smoking-cessation products. We look forward to Justin coming on board soon to accelerate and successfully deliver the next phase of Vitura's transformation.”
Mr James currently holds governance roles, including as a non-executive director and audit and risk chair at the Australian Medical Association, Western Australia, as well as chair of the disability support organisation Allevia. He also previously held senior responsibilities at Bupa Health Insurance, where he managed a multibillion-dollar revenue portfolio and large international teams.
Vitura Health is a diversified digital health platform operating across multiple segments of the healthcare ecosystem, with a particular emphasis on medicinal cannabis, telehealth and emerging therapies. Through its subsidiaries and joint ventures, the company runs a network of businesses including Burleigh Heads Cannabis and its Canview platform, which connects prescribers, pharmacies and patients in an integrated online ecosystem for therapeutic products. It also operates Doctors on Demand, a nationwide telehealth service providing round-the-clock medical consultations, along with Candor Medical, CDA Clinics and Cannadoc, which focus on patient access to medicinal cannabis through telehealth channels. In addition, Vitura holds interests in Releaf clinics and Cortexa, a joint venture focused on supplying pharmaceutical-grade psychedelic treatments such as MDMA and psilocybin for research and therapeutic use.